Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
about
Enoxaparin 0.3 mg/kg IV supplement for patients transitioning to PCI after subcutaneous enoxaparin therapy for NSTE ACS: a subgroup analysis from the SYNERGY trial.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@en
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@nl
type
label
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@en
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@nl
prefLabel
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@en
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@nl
P2093
P50
P356
P1476
Enoxaparin 0.3 mg/kg IV supple ...... alysis from the SYNERGY trial.
@en
P2093
Glenn N Levine
Harvey D White
Marc Cohen
Neal S Kleiman
Philip E Aylward
SYNERGY Trial Investigators
P304
P356
10.1002/CCD.22340
P577
2010-05-01T00:00:00Z